NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

CancerMelanoma Stage IIIMelanoma Stage IVCutaneous Melanoma

Interventions

BIOLOGICAL

KB707

Genetically modified herpes simplex type 1 virus

DRUG

Opdualag

Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)

DRUG

KEYTRUDA ®( Pembrolizumab)

Immunotherapy (PD-1 immune checkpoint inhibitor)

Trial Locations (15)

10065

RECRUITING

Weill Cornell Medicine-New York-Presbyterian Hospital, New York

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

33326

RECRUITING

BRCR Global, Weston

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

44718

RECRUITING

Gabrail Cancer Center Research, Canton

46202

RECRUITING

IU Simon Comprehensive Cancer Center, Indianapolis

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

68198

RECRUITING

University of Nebraska Medical Center, Omaha

77030

RECRUITING

MD Anderson Cancer Center, Houston

77380

RECRUITING

Renovatio Clinical - The Woodlands, The Woodlands

79915

RECRUITING

Renovatio Clinical - El Paso, El Paso

90095

RECRUITING

UCLA Health, Los Angeles

92688

RECRUITING

Mission Dermatology Center, Rancho Santa Margarita

07960

RECRUITING

Morristown Medical Center / Atlantic Health System, Morristown